HMTV yields 27.97% · PFE yields 6.13%● Live data
📍 HMTV pulled ahead of the other in Year 1
Combined, HMTV + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HMTV + PFE for your $10,000?
Hemisphere Media Group, Inc. operates as the Spanish-language media company. The company operates Pantaya, a subscription streaming service of Spanish-language media with approximately million subscribers; Cinelatino, a cable movie network with approximately 17.1 million subscribers in the United States, Latin America, and Canada; WAPA, a broadcast television network and television content producer; WAPA.TV, a news and entertainment website, as well as mobile apps, featuring content produced by WAPA; and WAPA Deportes, a sports television network in Puerto Rico. It also operates WAPA America, a cable television network that serves approximately 3.3 million subscribers in the United States; and Pasiones, a cable television network, which showcases telenovelas and serialized dramas to approximately 3.7 million subscribers in the United States and 15.4 million subscribers in Latin America. In addition, the company operates Centroamerica TV, a cable television network that provides news and entertainment, and soccer programming to approximately 3.2 million subscribers in the United States; and Television Dominicana, a cable television network, which offers news and entertainment programs to approximately 2.2 million subscribers in the United States. Further, it operates Snap Media, a distributor of content to broadcast and cable television networks; and over-the-top, and subscription and advertising video-on-demand platforms in Latin America; and REMEZCLA: a digital media company targeting English-speaking and the bilingual U.S. Hispanic millennials. The company was incorporated in 2013 and is headquartered in Coral Gables, Florida. As of September 13, 2022, Hemisphere Media Group, Inc. was taken private.
Full HMTV Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.